pantoprazole has been researched along with s 1743 in 121 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 56 (46.28) | 29.6817 |
| 2010's | 52 (42.98) | 24.3611 |
| 2020's | 13 (10.74) | 2.80 |
| Authors | Studies |
|---|---|
| Kromer, W | 1 |
| Tahboub, RM; Vanderhoff, BT | 1 |
| Cheer, SM; Faulds, D; Lamb, HM; Prakash, A | 1 |
| Hogan, D; Pratha, V; Sachs, G; Shin, JM | 1 |
| Gatz, G; Huber, R; Mascher, H; Müller, P; Pascu, O; Sander, P; Simon, B | 1 |
| Hellström, PM; Vitols, S | 1 |
| Gatz, G; Hole, U; Scholten, T | 1 |
| Armstrong, D; Bair, D; Escobedo, S; James, C; Nevin, K; Tanser, L | 1 |
| Chen, Y; Katz, PO; Miner, P; Sostek, M | 1 |
| Beil, W; Gatz, G; Gillessen, A; Hole, U; Modlin, IM | 1 |
| Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H | 1 |
| Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L | 1 |
| Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Arancia, G; Belardelli, F; De Milito, A; Fais, S; Federici, C; Iessi, E; Logozzi, M; Lozupone, F; Luciani, F; Lugini, L; Marra, M; Molinari, A; Montinaro, A; Parmiani, G; Rivoltini, L; Spada, M | 1 |
| Ahlbom, H; Bondarov, P; Hallerbäck, B; Röhss, K; Svedberg, LE; Wilder-Smith, CH | 1 |
| Orr, WC | 1 |
| Kuhlisch, E; Madisch, A; Miehlke, S | 1 |
| Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G | 1 |
| Kirsch, C; Knoth, H; Kuhlisch, E; Laass, M; Labenz, J; Lindner, F; Madisch, A; Miehlke, S; Morgner, A | 1 |
| Bardhan, KD; Gatz, G; Hein, J; Mönnikes, H; Pfaffenberger, B | 2 |
| Adler, J; Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G | 1 |
| Brown, RE; Remák, E; Robinson, A; Yuen, C | 1 |
| Chen, JL; Chen, WC; Cheng, JS; Hsu, PI; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Tsay, FW; Tseng, HH; Wu, CJ; Yamaoka, Y; Yu, HC | 1 |
| Calvet, X; Gomollón, F | 1 |
| Baker, DE | 1 |
| Goldstein, JL; Liu, S; Miner, PB; Schlesinger, PK; Silberg, DG | 1 |
| Clark, DW; Strandell, J | 1 |
| Ferrara, EC; Manes, G; Porro, GB | 1 |
| Castell, DO; Liu, S; Miner, PB; Sostek, MB; Tutuian, R | 1 |
| Edwards, SJ; Lind, T; Lundell, L | 1 |
| Begić, I; Bozić, D; Gmajnić, R; Jurcić, D; Khaznadar, E; Kondza, G; Mićunović, N; Ostojić, R; Soldo, I; Vcev, A | 1 |
| Abdel-Qader, M; Gatz, G; Glatzel, D; Pfaffenberger, B | 2 |
| Damian, U; Eickhoff, A; Hartmann, D; Riemann, JF; Schilling, D | 1 |
| Benamouzig, R; Goh, KL; Sander, P; Schwan, T | 1 |
| Molnar, B; Mullner, K; Tulassay, Z | 1 |
| Achim, A; Bardhan, KD; Pfaffenberger, B; Riddermann, T | 1 |
| Thomson, AB | 1 |
| Cho, YK; Choi, HS; Hwang, SJ; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JS; Sohn, CI | 1 |
| Beglinger, C; Degen, L; Hadengue, A; Ory, G; Piccoli, F | 1 |
| Pai, N; Pai, V | 1 |
| Andersson, T; Weidolf, L | 1 |
| Backlund, A; Eckerwall, G; Fjellman, M; Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S | 1 |
| Chang, IJ; Jung, HC; Kang, JM; Kim, JS; Kim, N; Lee, DH; Park, YS; Song, IS | 1 |
| Calvet, X; Garcia, P; Gisbert, JP; Vergara, M; Villoria, A | 1 |
| Gursoy, O; Memiş, D; Sut, N | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Christ, G; Jilma, B; Kreiner, G; Lang, IM; Siller-Matula, JM; Spiel, AO | 1 |
| Brunet, C; Dine, T; Dupin-Spriet, T; Gressier, B; Kambia, NK; Luyckx, M | 1 |
| Armstrong, D; Eklund, S; Labenz, J; Leodolter, A; Zetterstrand, S | 2 |
| Zheng, RN | 1 |
| Braun, S; Hadamitzky, M; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N | 1 |
| Geus, WP; Hunfeld, NG; Kooiman, JC; Kuipers, EJ; Mathot, RA; Mulder, PG; Touw, DJ; VAN Schaik, RH | 1 |
| Banerjee, R; Darisetty, S; Guda, NM; Kalpala, R; Mahurkar, S; Rao, GV; Reddy, DN | 1 |
| Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y | 1 |
| Binkley, P; Donnally, MR; Evanchan, J; Mazzaferri, E | 1 |
| Börgel, J; Endres, HG; Engelhardt, A; Krüger, JC; Lask, S; Mügge, A; Neubauer, H | 1 |
| Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J | 1 |
| Bethke, TD; Drewelow, B; Reitmeir, P; Schaffler, K | 1 |
| Bellini, M; Bianchi, G; Blandizzi, C; Ciancia, E; Costa, F; de Bortoli, N; Gambaccini, D; Lenzi, F; Leonardi, G; Maltinti, S; Marchi, S; Martinucci, I; Mumolo, MG; Piaggi, P; Ricchiuti, A | 1 |
| Deneer, VH; Hackeng, CM; Harmsze, AM; Taubert, D; van Werkum, JW | 1 |
| Hasenfuss, G; Maier, L; Schillinger, W; Schmitto, J; Schotola, H; Schwörer, H; Sohns, C; Sossalla, S; Toischer, K | 1 |
| Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Rostami-Hodjegan, A; Toren, P; Yerino, P | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B | 1 |
| Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S | 1 |
| Arroyo-Villarino, MT; Bujanda, L; Calleja, JL; Calvet, X; Feu, F; García, S; García-Rodríguez, LA; Lanas, A; Perez-Aisa, A; Polo-Tomas, M; Ponce, J; Sung, JJ | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Almebayadh, M; Avril, MF; Carlotti, A; Dupin, N; Goulvestre, C; Le Guern, V; Mouthon, L; Regnier-Rosencher, E | 1 |
| Hatlebakk, JG; Jonasson, C; Tvete, IF | 1 |
| Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C | 1 |
| Moraes-Filho, JP; Pedroso, M; Quigley, EM | 2 |
| Dhaliwal, A; Nwokolo, C | 1 |
| Antonelli, A; Bellini, M; de Bortoli, N; Frazzoni, M; Marchi, S; Martinucci, I; Piaggi, P; Savarino, E; Savarino, V | 1 |
| Schmutz, JL; Trechot, P | 1 |
| Alaa, H; Belal, F; Sharaf El-Din, M; Tolba, MM | 1 |
| Arroyo-Villarino, MT; Bujanda, L; Calleja, JL; Calvet, X; Carrera-Lasfuentes, P; Feu, F; García, S; García-Rodríguez, LA; Lanas, A; Perez-Aisa, A; Polo-Tomas, M; Ponce, J | 1 |
| Donnerer, J; Maieron, A; Schiller, D; Schöfl, R | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Bišćanin, A; Bratanić, A; Budimir, I; Hrabar, D; Ljubičić, N; Nikolić, M; Pavić, T; Puljiz, Ž; Troskot, B | 1 |
| Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
| Akers, KS; Boyd, NK; Niece, KL | 1 |
| Alber, H; Amann, A; Beer, B; Hofstaetter, S; Klieber, M; Modak, A; Neururer, M; Oberacher, H | 1 |
| Becker, ML; Franken, WP; Karapinar, F; Schalekamp, T; van der Hoeven, RT; Verzijl-Zeegers, R | 1 |
| Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M | 1 |
| Barbeau, G; Bertrand, OF; De Larochellière, R; Déry, JP; Déry, U; Gleeton, O; Harvey, A; Larose, É; Modak, A; Nguyen, CM; Noël, B; Paradis, JM; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L; Roy, M | 1 |
| Grzegrzolka, J; Petryszyn, P; Staniak, A | 1 |
| Aksoy Gökmen, A; Girginkardeşler, N; Kilimcioğlu, AA; Özbilgin, A; Şirin, MC | 1 |
| Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J | 1 |
| Ebbelaar, CF; Lammers, HA; Schobben, AF | 1 |
| Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP | 1 |
| Badowski, M; Hung, YT; Law, EH; Lee, TA; Sanchez, A; Weems, K | 1 |
| Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö | 1 |
| Klyarytska, I; Kriviy, V; Modak, AS; Rabotyagova, Y; Tsapyak, T | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Cho, WS; Jahng, J; Kim, HK; Kim, NH; Kim, YS; Lee, JW; Oh, BS; Park, JE; Park, JS; Woo, YS; Yoon, BW | 1 |
| Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X | 1 |
| Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J | 1 |
| Amazonas, RB; Bocchi de Oliveira, MF; Ecclissato, C; Macêdo, EA; Pott Júnior, H; Scheinberg, M | 1 |
| Burckart, GJ; Crentsil, V; Duan, P; Fisher, J; Gonzalez, D; Moore, JN; Wang, J; Wu, F; Zhang, L | 1 |
| Türkeş, C | 1 |
| Kan, LD; Li, LC; Wu, CY; Ying, J; Yu, ZW | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Hecht, S; Kuhl, A; Marshall, K; Odunayo, A; Price, J; Steiner, J; Tolbert, MK | 1 |
| Blesl, A; Feldbacher, N; Horvath, A; Komarova, I; Leber, B; Rainer, F; Stadlbauer, V; Steinwender, M | 1 |
| Baddam, R; Gone, V; Pasupuleti, B; Prasad, OP; Venisetty, RK | 1 |
| Barbeito Castiñeiras, G; Bardán García, B; Belles Medall, D; Blanco Dorado, S; Blanco Hortas, A; Campos-Toimil, M; Carracedo, Á; Fernández-Ferreiro, A; Gómez Márquez, A; Lamas, MJ; Latorre-Pellicer, A; López-Vizcaíno, A; Maroñas Amigo, O; Otero Espinar, F; Pérez Del Molino Bernal, ML; Rodríguez Jato, MT; Zarra Ferro, I | 1 |
| Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME | 1 |
| Backman, JT; Isoherranen, N; Kaartinen, TJK; Launiainen, T; Niemi, M; Tapaninen, T; Tornio, A | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Chen, W; Dzika, E; Lepczyńska, M; Lu, CY | 1 |
| Hancu, G; Kelemen, H; Papp, LA; Tóth, G | 1 |
| Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Lee, WP | 1 |
| Afzal, NA; Andrews, E; Beattie, RM; Hayen, A; Liddicoat, I; Tighe, MP | 1 |
21 review(s) available for pantoprazole and s 1743
| Article | Year |
|---|---|
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Pantoprazole; Peptic Ulcer; Sulfoxides; Zollinger-Ellison Syndrome | 2003 |
Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Time Factors | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2003 |
Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Sulfoxides | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Intravenous proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Biological Availability; Drug Interactions; Esomeprazole; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Lansoprazole; Pantoprazole; Proton Pump Inhibitors; Stomach; Sulfoxides | 2006 |
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2006 |
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2007 |
The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Databases, Factual; Esomeprazole; Gastroesophageal Reflux; Humans; Pantoprazole; Proton Pump Inhibitors; Psychometrics; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2007 |
Recent advances in chirally pure proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Isomerism; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Stereoselective disposition of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2008 |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2008 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing | 2010 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cost-Benefit Analysis; Esomeprazole; Gastroesophageal Reflux; Humans; Pantoprazole; Poland; Proton Pump Inhibitors; Treatment Outcome | 2016 |
Association Between Proton Pump Inhibitors and Microscopic Colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Colitis, Microscopic; Dose-Response Relationship, Drug; Esomeprazole; Humans; Omeprazole; Pantoprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2017 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electrophoresis; Esomeprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2021 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
Pharmacological treatment of gastro-oesophageal reflux in children.
Topics: Adolescent; Child; Esomeprazole; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine | 2023 |
43 trial(s) available for pantoprazole and s 1743
| Article | Year |
|---|---|
Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Pantoprazole; Sulfoxides | 2003 |
Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole; Sulfoxides; Surveys and Questionnaires; Treatment Outcome | 2003 |
Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Male; Pantoprazole; Sulfoxides | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Endoscopes, Gastrointestinal; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Pantoprazole; Sulfoxides; Treatment Outcome; Upper Gastrointestinal Tract | 2004 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Esomeprazole; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Urea | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Male; Middle Aged; Pantoprazole; Sulfoxides; Treatment Outcome | 2004 |
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Middle Aged; Pantoprazole; Sulfoxides; Treatment Outcome | 2005 |
Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides | 2005 |
Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Endoscopy, Gastrointestinal; Esomeprazole; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole; Quality of Life; Safety; Severity of Illness Index; Sulfoxides; Surveys and Questionnaires; Treatment Outcome | 2005 |
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Drug Tolerance; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Esophagoscopy; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Secondary Prevention; Sulfoxides; Treatment Outcome | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Patient Compliance; Peptic Ulcer; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2005 |
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2006 |
Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Algorithms; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Female; Gastric Acid; Humans; Infusions, Intravenous; Male; Middle Aged; Oklahoma; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Time Factors | 2006 |
Esomeprazole versus pantoprazole for healing erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole; Severity of Illness Index; Sulfoxides; Treatment Outcome | 2006 |
Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Esophagoscopy; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pain Measurement; Pantoprazole; Patient Satisfaction; Probability; Reference Values; Risk Assessment; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2006 |
Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Body Constitution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Monitoring, Physiologic; Pantoprazole | 2007 |
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Remission Induction; Secondary Prevention; Treatment Outcome | 2007 |
Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Esophagoscopy; Female; Follow-Up Studies; Gastroesophageal Reflux; Gastroscopy; Humans; Male; Middle Aged; Pantoprazole; Probability; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esomeprazole; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole; Probability; Reference Values; Secondary Prevention; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2007 |
A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole; Remission Induction; Secondary Prevention; Treatment Outcome; Wound Healing | 2007 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Analysis of Variance; Anti-Ulcer Agents; Cross-Over Studies; Electrodes; Esomeprazole; Female; Gastric Acidity Determination; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Male; Middle Aged; Pantoprazole; Prospective Studies; Stomach | 2007 |
Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Esomeprazole; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole | 2008 |
Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Critical Illness; Double-Blind Method; Esomeprazole; Female; Gastric Acidity Determination; Gastric Juice; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2008 |
Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2009 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Selection | 2009 |
Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Regression Analysis; Secondary Prevention; Time Factors; Treatment Outcome; Young Adult | 2009 |
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Monitoring, Physiologic; Pantoprazole; Polymorphism, Genetic; Time Factors; Treatment Outcome; Young Adult | 2010 |
Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Buffers; Chemistry, Pharmaceutical; Cross-Over Studies; Down-Regulation; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Male; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Sodium Bicarbonate; Telemetry; Time Factors; Young Adult | 2010 |
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Regression Analysis; Stents; Ticlopidine | 2010 |
Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Therapy, Combination; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Hispanic or Latino; Humans; Lansoprazole; Male; Middle Aged; Pantoprazole; Patient Compliance; Treatment Outcome; United States; Young Adult | 2010 |
Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Arousal; Cognition; Cross-Over Studies; Diazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electrooculography; Esomeprazole; Female; Humans; Hypnotics and Sedatives; Injections, Intravenous; Male; Middle Aged; Pantoprazole; Photic Stimulation; Proton Pump Inhibitors; Psychomotor Performance; Saccades; Young Adult | 2010 |
Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Apoptosis; Barrett Esophagus; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Esomeprazole; Esophageal pH Monitoring; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2011 |
Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Endoscopy; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Remission Induction; Treatment Outcome; Young Adult | 2014 |
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult | 2015 |
Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Blood Platelets; Breath Tests; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Esomeprazole; Humans; Omeprazole; Pantoprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Ranitidine; Ticlopidine | 2016 |
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2016 |
The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Biomarkers; Breath Tests; Carbon Radioisotopes; Cytochrome P-450 CYP2C19; Esomeprazole; Female; Gastroesophageal Reflux; Genetic Association Studies; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Pharmacogenetics; Precision Medicine; Proton Pump Inhibitors; Young Adult | 2016 |
Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Esomeprazole; Female; Humans; Male; Middle Aged; Naproxen; Osteoporosis; Pain; Pain Management; Pantoprazole; Sulfonamides; Tablets | 2018 |
Comparative analysis of the effect of IV administered acid suppressants on gastric pH in dogs.
Topics: Animals; Anti-Ulcer Agents; Cross-Over Studies; Dogs; Esomeprazole; Famotidine; Female; Hydrogen-Ion Concentration; Injections, Intravenous; Male; Pantoprazole | 2020 |
Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
Topics: Anticonvulsants; Clobazam; Drug Interactions; Esomeprazole; Female; Humans; Levetiracetam; Male; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2020 |
57 other study(ies) available for pantoprazole and s 1743
| Article | Year |
|---|---|
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
[Exaggerated interaction claims. With esomeprazole the data corroborate safety].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Esomeprazole; Humans; Pantoprazole; Proton Pumps; Sulfoxides | 2003 |
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides | 2004 |
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Esomeprazole; Fluorouracil; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Inhibitory Concentration 50; Lymphoma; Melanoma; Mice; Mice, SCID; Microscopy, Confocal; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Transplantation, Heterologous; Vinblastine | 2004 |
A randomized controlled trial of equivalence between pantoprazole and esomeprazole that does not have the power to conclude.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Pantoprazole; Randomized Controlled Trials as Topic; Sulfoxides; Therapeutic Equivalency; Treatment Outcome | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom | 2005 |
Eradication of Helicobacter pylori and dosages of esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2006 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole | 2008 |
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Outcome | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2009 |
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Color; Drug Incompatibility; Drug Stability; Drug Storage; Esomeprazole; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Nefopam; Omeprazole; Pantoprazole; Pharmaceutical Solutions; Proton Pump Inhibitors; Temperature; Time Factors | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Clopidogrel; Confidence Intervals; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pantoprazole; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Treatment Failure | 2010 |
Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel's active metabolite.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clopidogrel; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Female; Humans; Male; Middle Aged; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Esomeprazole; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Kinetics; Myocardial Contraction; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Ventricular Function, Right | 2011 |
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Inhibitory Concentration 50; Lansoprazole; Microsomes; Microsomes, Liver; Omeprazole; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine | 2011 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult | 2012 |
Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Confidence Intervals; Esomeprazole; Female; Hematemesis; Hemostasis, Endoscopic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Shock; Spain | 2013 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2013 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; Health Policy; Humans; Insurance, Health, Reimbursement; Lansoprazole; Norway; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2013 |
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents | 2014 |
Commentary: daily pantoprazole vs. esomeprazole for GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Pantoprazole; Proton Pump Inhibitors | 2014 |
Commentary: daily pantoprazole vs. esomeprazole for GERD--authors' reply.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Pantoprazole; Proton Pump Inhibitors | 2014 |
Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electric Impedance; Esomeprazole; Esophageal pH Monitoring; Esophagus; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors | 2014 |
[Lupus erythematosus and proto-pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Autoantibodies; Biopsy; Diagnosis, Differential; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Skin | 2014 |
Enhanced spectrofluorimetric determination of esomeprazole and pantoprazole in dosage forms and spiked human plasma using organized media.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Capsules; Esomeprazole; Humans; Hydrogen-Ion Concentration; Limit of Detection; Methylcellulose; Pantoprazole; Reproducibility of Results; Sodium Dodecyl Sulfate; Solvents; Spectrometry, Fluorescence; Tablets | 2015 |
Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Endoscopy, Gastrointestinal; Esomeprazole; Female; Hemostasis, Endoscopic; Hospitalization; Humans; Male; Middle Aged; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
Drug fever due to a single dose of pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Hypersensitivity; Esomeprazole; Female; Fever; Humans; Leukocytosis; Pantoprazole; Proton Pump Inhibitors | 2014 |
North vs south differences in acute peptic ulcer hemorrhage in Croatia: hospitalization incidence trends, clinical features, and 30-day case fatality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Age Distribution; Aged; Aged, 80 and over; Anti-Ulcer Agents; Croatia; Epinephrine; Esomeprazole; Female; Geography; Hospitalization; Humans; Incidence; Male; Middle Aged; Pantoprazole; Peptic Ulcer Hemorrhage; Risk Factors; Sex Distribution; Vasoconstrictor Agents | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole | 2015 |
CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Cytochrome P-450 CYP2C19; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Precision Medicine; Proton Pump Inhibitors; Reproducibility of Results; Young Adult | 2015 |
Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acenocoumarol; Aged; Aged, 80 and over; Anti-Ulcer Agents; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Esomeprazole; Female; Hospitalization; Hospitals, Teaching; Humans; International Normalized Ratio; Male; Omeprazole; Pantoprazole; Phenprocoumon | 2015 |
[In vitro susceptibility of Trichomonas vaginalis to metronidazole, ornidazole and proton pump inhibitors pantoprazole and esomeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antitrichomonal Agents; Cryopreservation; Drug Resistance; Esomeprazole; Humans; Metronidazole; Ornidazole; Pantoprazole; Parasitic Sensitivity Tests; Proton Pump Inhibitors; Time Factors; Trichomonas vaginalis | 2016 |
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
[Switching to a generic drugA blessing or a curse?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drugs, Generic; Esomeprazole; Humans; Pantoprazole; Rabeprazole; Treatment Outcome; Zollinger-Ellison Syndrome | 2016 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan | 2017 |
[Trend in the Eradication Rates of
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Probiotics; Proton Pump Inhibitors; Republic of Korea; Retrospective Studies; Sex Factors; Treatment Outcome | 2017 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2018 |
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult | 2019 |
Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition.
Topics: Adolescent; Adult; Child; Child, Preschool; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Esomeprazole; Humans; Infant; Infant, Newborn; Models, Biological; Pantoprazole; Proton Pump Inhibitors | 2019 |
A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors.
Topics: Aryldialkylphosphatase; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Risk Factors | 2019 |
The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; China; Comorbidity; Esomeprazole; Female; Health Care Surveys; Hospitals; Humans; Inappropriate Prescribing; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2019 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study.
Topics: Aged; Alkaline Phosphatase; Anti-Ulcer Agents; Aspartate Aminotransferases; Bacillus; Clostridiales; Dysbiosis; Esomeprazole; Female; Gastroesophageal Reflux; Gastrointestinal Microbiome; Gene Expression Regulation; Haptoglobins; Humans; Lactobacillus; Lactococcus; Leukocyte L1 Antigen Complex; Male; Middle Aged; Pantoprazole; Peptic Ulcer; Pilot Projects; Prebiotics; Probiotics; Protein Precursors; Proton Pump Inhibitors; Quality of Life | 2020 |
A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Voriconazole | 2020 |
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry | 2020 |
Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.
Topics: Administration, Oral; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Esomeprazole; Female; Healthy Volunteers; Humans; Male; Midazolam; Models, Biological; Pantoprazole; Pharmacogenomic Variants | 2020 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
Influence of Proton Pump Inhibitors and Histamine Receptor 2 Antagonists on Blastocystis ST3 and Selected Microorganisms of Intestinal Microbiota In Vitro.
Topics: Anti-Infective Agents; Blastocystis; Candida albicans; Enterococcus faecium; Escherichia coli; Esomeprazole; Gastrointestinal Microbiome; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lacticaseibacillus rhamnosus; Metronidazole; Microbial Sensitivity Tests; Pantoprazole; Proton Pump Inhibitors | 2021 |
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors.
Topics: Activating Transcription Factor 6; Dexlansoprazole; Endoplasmic Reticulum Stress; Esomeprazole; Humans; Pantoprazole; Protein Serine-Threonine Kinases; Proton Pump Inhibitors; Rabeprazole; Reactive Oxygen Species; Stomach Neoplasms; Superoxide Dismutase; Vacuolar Proton-Translocating ATPases | 2022 |